Molecular subtyping of metastatic melanoma based on cell ganglioside metabolism profiles

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Tringali, Cristina ^a   Silvestri, Ilaria ^a   Testa, Francesca ^a   Baldassari, Paola ^b   Anastasia, Luigi ^c,d   Mortarini, Roberta ^b   Anichini, Andrea ^b   López Requena, Alejandro ^e   Tettamanti, Guido ^c   Venerando, Bruno ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c IRCCS POLICLINICO SAN DONATO   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

^e CENTER OF MOLECULAR IMMUNOLOGY   (Cuba)

Author keywords

Ganglioside; Melanoma; N glycolyl GM3; Sialidase; Survival

Indexed keywords

BETA 1,4 N ACETYL GALACTOSAMINYLTRANSFERASE 1; GANGLIOSIDE; GANGLIOSIDE GALACTOSYLTRANSFERASE; GANGLIOSIDE GD3; GANGLIOSIDE GM3; N ACETYLGALACTOSAMINYLTRANSFERASE; PROTEIN NEU3; SIALIDASE; SYNTHETASE; UNCLASSIFIED DRUG; GLYCOSYLTRANSFERASE;

ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CELL INVASION; CELL METABOLISM; CELL PROLIFERATION; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; LIPID ANALYSIS; LIPID METABOLISM; MELANOMA CELL LINE; METASTATIC MELANOMA; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; CLUSTER ANALYSIS; GENE EXPRESSION REGULATION; MELANOMA; METABOLISM; METASTASIS; PATHOLOGY; PROGNOSIS; SURVIVAL; TUMOR CELL CULTURE;

CLUSTER ANALYSIS; GANGLIOSIDES; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOSYLTRANSFERASES; HUMANS; MELANOMA; NEOPLASM METASTASIS; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR CELLS, CULTURED;

EID: 84905820841     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-560     Document Type: Article

References (60)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108.
2. Miller AJ, Mihm MC. Melanoma. N Engl J Med 2006, 355:51-65.
3. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG, Ding S, Eggermont AM, Flaherty KT, Gimotty PA, Kirkwood JM, McMasters KM, Mihm M, Morton DL, Ross MI, Sober AJ, Sondak VK. Final version of AJCC melanoma staging and classification. J Clin Oncol 2009, 2009(27):6199-6206.
4. Thompson JF, Scolyer RA, Kefford RF. Cutaneous melanoma. Lancet 2005, 365:687-701.
5. Haass NK, Smalley KS. Melanoma biomarkers: current status and utility in diagnosis, prognosis, and response to therapy. Mol Diagn Ther 2009, 13:283-296.
6. Gould Rothberg BE, Rimm DL. Biomarkers: the useful and the not so useful-an assessment of molecular prognostic markers for cutaneous melanoma. J Invest Dermatol 2010, 130:1971-1987.
7. Baruthio F, Quadroni M, Ruegg C, Mariotti A. Proteomic analysis of membrane rafts of melanoma cells identifies protein patterns characteristic of the tumor progression stage. Proteomics 2008, 8:4733-4747.
8. Brunner G, Reitz M, Heinecke A, Lippold A, Berking C, Suter L, Atzpodien J. A nine-gene signature predicting clinical outcome in cutaneous melanoma. J Cancer Res Clin Oncol 2013, 139:249-258.
9. Schramm SJ, Campain AE, Scolyer RA, Yang YH, Mann GJ. Review and cross-validation of gene expression signatures and melanoma prognosis. J Invest Dermatol 2012, 132:274-283.
10. Hakomori S. Tumor-associated carbohydrate antigens defining tumor malignancy: basis for development of anti-cancer vaccines. Adv Exp Med Biol 2001, 491:369-402.
11. Ruan S, Raj BK, Lloyd KO. Relationship of glycosyltransferases and mRNA levels to ganglioside expression in neuroblastoma and melanoma cells. J Neurochem 1999, 72:514-521.
12. Portoukalian J, Zwingelstein G, Dore JF. Lipid composition of human malignant melanoma tumors at various levels of malignant growth. Eur J Biochem 1979, 94:19-23.
13. Carubia JM, Yu RK, Macala LJ, Kirkwood JM, Varga JM. Gangliosides of normal and neoplastic human melanocytes. Biochem Biophys Res Commun 1984, 120:500-504.
14. Yu RK, Macala LJ, Taki T, Weinfield HM, Yu FS. Developmental changes in ganglioside composition and synthesis in embryonic rat brain. J Neurochem 1988, 50:1825-1829.
15. Welte K, Miller G, Chapman PB, Yuasa H, Natoli E, Kunicka JE, Cordon-Cardo C, Buhrer C, Old LJ, Houghton AN. Stimulation of T lymphocyte proliferation by monoclonal antibodies against GD3 ganglioside. J Immunol 1987, 139:1763-1771.
16. Yamashiro S, Okada M, Haraguchi M, Furukawa K, Lloyd KO, Shiku H, Furukawa K. Expression of alpha 2,8-sialyltransferase (GD3 synthase) gene in human cancer cell lines: high level expression in melanomas and up-regulation in activated T lymphocytes. Glycoconj J 1995, 12:894-900.
17. Furukawa K, Hamamura K, Nakashima H, Furukawa K. Molecules in the signaling pathway activated by gangliosides can be targets of therapeutics for malignant melanomas. Proteomics 2008, 8:3312-3316.
18. Liu JW, Sun P, Yan Q, Paller AS, Gerami P, Ho N, Vashi N, Le Poole IC, Wang XQ. De-N-acetyl GM3 promotes melanoma cell migration and invasion through urokinase plasminogen activator receptor signaling-dependent MMP-2 activation. Cancer Res 2009, 69:8662-8669.
19. Blanco R, Rengifo E, Rengifo CE, Cedeno M, Frometa M, Carr A. Immunohistochemical Reactivity of the 14 F7 Monoclonal Antibody Raised against N-Glycolyl GM3 Ganglioside in Some Benign and Malignant Skin Neoplasms. ISRN Dermatol 2011, 2011:848909.
20. Hamamura K, Furukawa K, Hayashi T, Hattori T, Nakano J, Nakashima H, Okuda T, Mizutani H, Hattori H, Ueda M, Urano T, Lloyd KO, Furukawa K. Ganglioside GD3 promotes cell growth and invasion through p130Cas and paxillin in malignant melanoma cells. Proc Natl Acad Sci U S A 2005, 102:11041-11046.
21. Miyata M, Kambe M, Tajima O, Moriya S, Sawaki H, Hotta H, Kondo Y, Narimatsu H, Miyagi T, Furukawa K, Furukawa K. Membrane sialidase NEU3 is highly expressed in human melanoma cells promoting cell growth with minimal changes in the composition of gangliosides. Cancer Sci 2011, 102:2139-2149.
22. Perotti V, Baldassari P, Bersani I, Molla A, Vegetti C, Tassi E, Dal Col J, Dolcetti R, Anichini A, Mortarini R. NFATc2 is a potential therapeutic target in human melanoma. J Invest Dermatol 2012, 132:2652-2660.
23. Tassi E, Zanon M, Vegetti C, Molla A, Bersani I, Perotti V, Pennati M, Zaffaroni N, Milella M, Ferrone S, Carlo-Stella C, Gianni AM, Mortarini R, Anichini A. Role of Apollon in human melanoma resistance to antitumor agents that activate the intrinsic or the extrinsic apoptosis pathways. Clin Cancer Res 2012, 18:3316-3327.
24. Daniotti M, Oggionni M, Ranzani T, Vallacchi V, Campi V, Di Stasi D, Torre GD, Perrone F, Luoni C, Suardi S, Frattini M, Pilotti S, Anichini A, Tragni G, Parmiani G, Pierotti MA, Rodolfo M. BRAF alterations are associated with complex mutational profiles in malignant melanoma. Oncogene 2004, 23:5968-5977.
25. Anichini A, Mortarini R, Nonaka D, Molla A, Vegetti C, Montaldi E, Wang X, Ferrone S. Association of antigen-processing machinery and HLA antigen phenotype of melanoma cells with survival in American Joint Committee on Cancer stage III and IV melanoma patients. Cancer Res 2006, 66:6405-6411.
26. Anichini A, Mazzocchi A, Fossati G, Parmiani G. Cytotoxic T lymphocyte clones from peripheral blood and from tumor site detect intratumor heterogeneity of melanoma cells. Analysis of specificity and mechanisms of interaction. J Immunol 1989, 142:3692-3701.
27. Sensi M, Nicolini G, Petti C, Bersani I, Lozupone F, Molla A, Vegetti C, Nonaka D, Mortarini R, Parmiani G, Fais S, Anichini A. Mutually exclusive NRASQ61R and BRAFV600E mutations at the single-cell level in the same human melanoma. Oncogene 2006, 25:3357-3364.
28. Tringali C, Lupo B, Cirillo F, Papini N, Anastasia L, Lamorte G, Colombi P, Bresciani R, Monti E, Tettamanti G, Venerando B. Silencing of membrane-associated sialidase Neu3 diminishes apoptosis resistance and triggers megakaryocytic differentiation of chronic myeloid leukemic cells K562 through the increase of ganglioside GM3. Cell Death Differ 2009, 16:164-174.
29. Scaringi R, Piccoli M, Papini N, Cirillo F, Conforti E, Bergante S, Tringali C, Garatti A, Gelfi C, Venerando B, Menicanti L, Tettamanti G, Anastasia L. NEU3 sialidase is activated under hypoxia and protects skeletal muscle cells from apoptosis through the activation of the epidermal growth factor receptor signaling pathway and the hypoxia-inducible factor (HIF)-1alpha. J Biol Chem 2013, 288:3153-3162.
30. Scandroglio F, Loberto N, Valsecchi M, Chigorno V, Prinetti A, Sonnino S. Thin layer chromatography of gangliosides. Glycoconj J 2009, 26:961-973.
31. Casadesus AV, Fernandez-Marrero Y, Clavell M, Gomez JA, Hernandez T, Moreno E, Lopez-Requena A. A shift from N-glycolyl- to N-acetyl-sialic acid in the GM3 ganglioside impairs tumor development in mouse lymphocytic leukemia cells. Glycoconj J 2013, 30:687-699.
32. Carr A, Mullet A, Mazorra Z, Vazquez AM, Alfonso M, Mesa C, Rengifo E, Perez R, Fernandez LE. A mouse IgG1 monoclonal antibody specific for N-glycolyl GM3 ganglioside recognized breast and melanoma tumors. Hybridoma 2000, 19:241-247.
33. Mortarini R, Gismondi A, Maggioni A, Santoni A, Herlyn M, Anichini A. Mitogenic activity of laminin on human melanoma and melanocytes: different signal requirements and role of beta 1 integrins. Cancer Res 1995, 55:4702-4710.
34. Tringali C, Cirillo F, Lamorte G, Papini N, Anastasia L, Lupo B, Silvestri I, Tettamanti G, Venerando B. NEU4L sialidase overexpression promotes beta-catenin signaling in neuroblastoma cells, enhancing stem-like malignant cell growth. Int J Cancer 2012, 131:1768-1778.
35. Tringali C, Lupo B, Silvestri I, Papini N, Anastasia L, Tettamanti G, Venerando B. The plasma membrane sialidase NEU3 regulates the malignancy of renal carcinoma cells by controlling beta1 integrin internalization and recycling. J Biol Chem 2012, 287:42835-42845.
36. Tringali C, Anastasia L, Papini N, Bianchi A, Ronzoni L, Cappellini MD, Monti E, Tettamanti G, Venerando B. Modification of sialidase levels and sialoglycoconjugate pattern during erythroid and erytroleukemic cell differentiation. Glycoconj J 2007, 24:67-79.
37. Papini N, Anastasia L, Tringali C, Croci G, Bresciani R, Yamaguchi K, Miyagi T, Preti A, Prinetti A, Prioni S, Sonnino S, Tettamanti G, Venerando B, Monti E. The plasma membrane-associated sialidase MmNEU3 modifies the ganglioside pattern of adjacent cells supporting its involvement in cell-to-cell interactions. J Biol Chem 2004, 279:16989-16995.
38. Malykh YN, Schauer R, Shaw L. N-Glycolylneuraminic acid in human tumours. Biochimie 2001, 83:623-634.
39. Varki A. N-glycolylneuraminic acid deficiency in humans. Biochimie 2001, 83:615-622.
40. Irie A, Suzuki A. CMP-N-Acetylneuraminic acid hydroxylase is exclusively inactive in humans. Biochem Biophys Res Commun 1998, 248:330-333.
41. Hedlund M, Tangvoranuntakul P, Takematsu H, Long JM, Housley GD, Kozutsumi Y, Suzuki A, Wynshaw-Boris A, Ryan AF, Gallo RL, Varki N, Varki A. N-glycolylneuraminic acid deficiency in mice: implications for human biology and evolution. Mol Cell Biol 2007, 27:4340-4346.
42. Yamaguchi K, Koseki K, Shiozaki M, Shimada Y, Wada T, Miyagi T. Regulation of plasma-membrane-associated sialidase NEU3 gene by Sp1/Sp3 transcription factors. Biochem J 2010, 430:107-117.
43. Furukawa K, Horie M, Okutomi K, Sugano S, Furukawa K. Isolation and functional analysis of the melanoma specific promoter region of human GD3 synthase gene. Biochim Biophys Acta 2003, 1627:71-78.
44. Seyfried TN, Yu RK. Ganglioside GD3: structure, cellular distribution, and possible function. Mol Cell Biochem 1985, 68:3-10.
45. Ohkawa Y, Miyazaki S, Hamamura K, Kambe M, Miyata M, Tajima O, Ohmi Y, Yamauchi Y, Furukawa K, Furukawa K. Ganglioside GD3 enhances adhesion signals and augments malignant properties of melanoma cells by recruiting integrins to glycolipid-enriched microdomains. J Biol Chem 2010, 285:27213-27223.
46. Cheresh DA, Reisfeld RA, Varki AP. O-acetylation of disialoganglioside GD3 by human melanoma cells creates a unique antigenic determinant. Science 1984, 225:844-846.
47. Schauer R. Sialic acids as regulators of molecular and cellular interactions. Curr Opin Struct Biol 2009, 19:507-514.
48. Nystedt J, Anderson H, Hirvonen T, Impola U, Jaatinen T, Heiskanen A, Blomqvist M, Satomaa T, Natunen J, Saarinen J, Lehenkari P, Valmu L, Laine J. Human CMP-N-acetylneuraminic acid hydroxylase is a novel stem cell marker linked to stem cell-specific mechanisms. Stem Cells 2010, 28:258-267.
49. Osorio M, Gracia E, Rodriguez E, Saurez G, Arango Mdel C, Noris E, Torriella A, Joan A, Gomez E, Anasagasti L, Gonza´lez JL, Melgares Mde L, Torres I, Gonza´lez J, Alonso D, Rengifo E, Carr A, Pe´rez R, Ferna´ndez LE. Heterophilic NeuGcGM3 ganglioside cancer vaccine in advanced melanoma patients: results of a Phase Ib/IIa study. Cancer Biol Ther 2008, 7:488-495.
50. Gabri MR, Otero LL, Gomez DE, Alonso DF. Exogenous incorporation of neugc-rich mucin augments n-glycolyl sialic acid content and promotes malignant phenotype in mouse tumor cell lines. J Exp Clin Cancer Res 2009, 28:146.
51. Hayashi N, Chiba H, Kuronuma K, Go S, Hasegawa Y, Takahashi M, Gasa S, Watanabe A, Hasegawa T, Kuroki Y, Inokuchi J, Takahashi H. Detection of N-glycolyated gangliosides in non-small-cell lung cancer using GMR8 monoclonal antibody. Cancer Sci 2013, 104:43-47.
52. de Leon J, Fernandez A, Mesa C, Clavel M, Fernandez LE. Role of tumour-associated N-glycolylated variant of GM3 ganglioside in cancer progression: effect over CD4 expression on T cells. Cancer Immunol Immunother 2006, 55:443-450.
53. de Leon J, Fernandez A, Clavell M, Labrada M, Bebelagua Y, Mesa C, Fernandez LE. Differential influence of the tumour-specific non-human sialic acid containing GM3 ganglioside on CD4 + CD25- effector and naturally occurring CD4 + CD25+ regulatory T cells function. Int Immunol 2008, 20:591-600.
54. Wang J, Yu RK. Interaction of ganglioside GD3 with an EGF receptor sustains the self-renewal ability of mouse neural stem cells in vitro. Proc Natl Acad Sci U S A 2013, 110:19137-19142.
55. Dong Y, Ikeda K, Hamamura K, Zhang Q, Kondo Y, Matsumoto Y, Ohmi Y, Yamauchi Y, Furukawa K, Taguchi R, Furukawa K. GM1/GD1b/GA1 synthase expression results in the reduced cancer phenotypes with modulation of composition and raft-localization of gangliosides in a melanoma cell line. Cancer Sci 2010, 101:2039-2047.
56. Bonaventure J, Domingues MJ, Larue L. Cellular and molecular mechanisms controlling the migration of melanocytes and melanoma cells. Pigment Cell Melanoma Res 2013, 26:316-325.
57. Kim SM, Jung JU, Ryu JS, Jin JW, Yang HJ, Ko K, You HK, Jung KY, Choo YK. Effects of gangliosides on the differentiation of human mesenchymal stem cells into osteoblasts by modulating epidermal growth factor receptors. Biochem Biophys Res Commun 2008, 371:866-871.
58. Ravindranath MH, Tsuchida T, Morton DL, Irie RF. Ganglioside GM3:GD3 ratio as an index for the management of melanoma. Cancer 1991, 67:3029-3035.
59. Kakugawa Y, Wada T, Yamaguchi K, Yamanami H, Ouchi K, Sato I, Miyagi T. Up-regulation of plasma membrane-associated ganglioside sialidase (Neu3) in human colon cancer and its involvement in apoptosis suppression. Proc Natl Acad Sci U S A 2002, 99:10718-10723.
60. Valaperta R, Chigorno V, Basso L, Prinetti A, Bresciani R, Preti A, Miyagi T, Sonnino S. Plasma membrane production of ceramide from ganglioside GM3 in human fibroblasts. FASEB J 2006, 20:1227-1229.